Addressing menopause symptoms in the primary care setting: opportunity to bridge care delivery gaps.

Autor:	Bevry ML; From the Department of Pharmacy Services Mayo Clinic Health System-Northwest Wisconsin Region, Eau Claire, WI., Stogdill ER; Department of Pharmacy Services, Mayo Clinic Health System-Northwest Wisconsin Region, Menomonie, WI., Lea CM; From the Department of Pharmacy Services Mayo Clinic Health System-Northwest Wisconsin Region, Eau Claire, WI., Taylor KR; Department of Pharmacy Services, Mayo Clinic Health System-Northwest Wisconsin Region, Chippewa Falls, WI., Lovaas AM; Department of Pharmacy Services, Mayo Clinic, Rochester, MN., Bailey KJ; From the Department of Pharmacy Services Mayo Clinic Health System-Northwest Wisconsin Region, Eau Claire, WI., Mara KC; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN., Dierkhising RA; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN., Chaudhry R, Faubion SS, Kapoor E
Jazyk:	angličtina
Zdroj:	Menopause (New York, N.Y.) [Menopause] 2024 Dec 01; Vol. 31 (12), pp. 1044-1048. Date of Electronic Publication: 2024 Oct 01.
DOI:	10.1097/GME.0000000000002439
Abstrakt:	Objective: Menopause symptoms affect quality of life and financial well-being but are often unaddressed in primary care clinics. Therefore, we evaluated the extent of menopause symptom documentation in electronic health records (EHRs) by primary health care professionals. Methods: We retrospectively reviewed adult women who reported moderate or higher vasomotor symptoms on a Mayo Clinic survey conducted from March 1, 2021, through June 30, 2021. We then assessed adequacy of menopause symptom documentation in the EHRs of these women who had primary care visits during the survey period. We reviewed the percentage of documented vasomotor symptoms from May 1, 2019, through May 1, 2021. Results: In the Mayo Clinic Health System-Northwest Wisconsin Region, 229 women self-reported moderate or higher vasomotor symptoms in the Mayo Clinic survey. Although only 23% of these women had vasomotor symptoms listed in the EHR clinical problem lists, 60% of these women had vasomotor symptoms documented in their clinic notes from the primary care visit. Approximately 6% of women reported hormone therapy use for management of menopause symptoms, and nearly 15% reported use of nonhormone prescription therapies for vasomotor symptoms. Conclusions: A greater proportion of women in our study had EHR documentation of bothersome menopause symptoms than those reported in other studies, but vasomotor symptoms remain generally untreated. We need better methods for identifying midlife women with bothersome menopause symptoms in primary care clinics so that appropriate treatment options, including hormone therapy, can be discussed and offered. Competing Interests: Financial disclosure/conflicts of interest: E.K.: consultant for Mithra Pharmaceuticals, Astellas Pharmaceuticals, and Womaness, grant support from Mithra Pharmaceuticals, advisory board for Scynexis. S.S.F.: past funding from Optum Health and Primed, current funding from Atria Health. The other authors have none reported. (Copyright © 2024 by The Menopause Society.)
Databáze:	MEDLINE
Externí odkaz: